Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00599924 · ClinicalTrials.gov registry record · Phase 1

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

A Phase 1 study of Neoplasms and Colorectal Neoplasms, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
53
Enrollment target
3
Study locations

NCT00599924 is a Phase 1 study of Neoplasms and Colorectal Neoplasms that has completed, run by Pfizer. The registered enrollment target is 53 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00599924, a Phase 1 study of Neoplasms and Colorectal Neoplasms, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
53 participants
Enrollment target
3
Study locations

Study Summary

This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX \[Leucovorin + Fluorouracil (5-FU) + Oxaliplatin\]. Three different dosing regimens with starting doses of sunitinib at 37.5 mg/day (Schedule 2/2, Schedule 4/2, and Continuous Dosing) were tested in patients with advanced solid tumors, including colorectal cancer.

Conditions Studied

Neoplasms Colorectal Neoplasms

Interventions

  • DRUG sunitinib + FOLFOX

Study Locations (3)

Colorado

  • Pfizer Investigational Site - Aurora

Tennessee

  • Pfizer Investigational Site - Nashville

Texas

  • Pfizer Investigational Site - Dallas

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2005-09
Est. Completion 2008-11
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00599924

The ClinicalTrials.gov registry entry for NCT00599924 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which sunitinib + FOLFOX is the first listed.

NCT00599924 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Tennessee, Texas.

Frequently Asked Questions

What is clinical trial NCT00599924 about?

NCT00599924 is a clinical study titled "Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors". This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX \[Leucovorin + Fluorouracil (5-FU) + Oxaliplatin\]. Three different dosing regimens with starting doses of sunitinib at 37.5 mg/day (Schedule 2/2, Schedule 4/2, and Continuou...

What is the current status of trial NCT00599924?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2005-09. Estimated completion is 2008-11.

What conditions does trial NCT00599924 study?

This clinical trial studies the following conditions: Neoplasms, Colorectal Neoplasms.

What interventions are being tested in trial NCT00599924?

The interventions under investigation include: sunitinib + FOLFOX (DRUG).

Who is sponsoring clinical trial NCT00599924?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00599924 being conducted?

This trial has 3 study locations across Colorado, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Colorectal Neoplasms

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.